SANARA MEDTECH INC (SMTI)
US79957L1008 - Common Stock
Overall SMTI gets a fundamental rating of 3 out of 10. We evaluated SMTI against 193 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of SMTI have multiple concerns. SMTI is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SMTI had negative earnings in the past year.
In the past year SMTI has reported a negative cash flow from operations.
SMTI had negative earnings in each of the past 5 years.
In the past 5 years SMTI always reported negative operating cash flow.
1.2 Ratios
SMTI has a better Return On Assets (-5.83%) than 61.66% of its industry peers.
SMTI has a Return On Equity of -9.61%. This is in the better half of the industry: SMTI outperforms 63.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.83% | ||
| ROE | -9.61% | ||
| ROIC | N/A |
ROA(3y)-13.53%
ROA(5y)-22.04%
ROE(3y)-18.14%
ROE(5y)-33.57%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 87.94%, SMTI belongs to the best of the industry, outperforming 96.89% of the companies in the same industry.
SMTI's Gross Margin has been stable in the last couple of years.
SMTI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 87.94% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.63%
GM growth 5Y-0.75%
2. Health
2.1 Basic Checks
SMTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
SMTI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SMTI has more shares outstanding
The debt/assets ratio for SMTI is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 5.89 indicates that SMTI is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 5.89, SMTI belongs to the best of the industry, outperforming 80.31% of the companies in the same industry.
SMTI has a Debt/Equity ratio of 0.20. This is a healthy value indicating a solid balance between debt and equity.
SMTI's Debt to Equity ratio of 0.20 is in line compared to the rest of the industry. SMTI outperforms 50.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.89 |
ROIC/WACCN/A
WACC9.58%
2.3 Liquidity
SMTI has a Current Ratio of 1.38. This is a normal value and indicates that SMTI is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.38, SMTI is doing worse than 84.97% of the companies in the same industry.
SMTI has a Quick Ratio of 1.04. This is a normal value and indicates that SMTI is financially healthy and should not expect problems in meeting its short term obligations.
SMTI has a worse Quick ratio (1.04) than 82.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.04 |
3. Growth
3.1 Past
SMTI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.32%, which is quite impressive.
The Revenue has grown by 41.78% in the past year. This is a very strong growth!
Measured over the past years, SMTI shows a very strong growth in Revenue. The Revenue has been growing by 61.91% on average per year.
EPS 1Y (TTM)47.32%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-50%
Revenue 1Y (TTM)41.78%
Revenue growth 3Y60.94%
Revenue growth 5Y61.91%
Revenue growth Q2Q19.44%
3.2 Future
The Earnings Per Share is expected to grow by 76.02% on average over the next years. This is a very strong growth
SMTI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.84% yearly.
EPS Next Y56.85%
EPS Next 2Y76.02%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year22.26%
Revenue Next 2Y18.84%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for SMTI. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 53.41, the valuation of SMTI can be described as expensive.
Based on the Price/Forward Earnings ratio, SMTI is valued a bit cheaper than 68.39% of the companies in the same industry.
SMTI's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 20.47.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 53.41 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
SMTI's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as SMTI's earnings are expected to grow with 76.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y76.02%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for SMTI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SANARA MEDTECH INC
NASDAQ:SMTI (5/17/2024, 3:30:02 PM)
After market: 30.51 0 (0%)30.51
-1.19 (-3.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap263.00M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 53.41 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.83% | ||
| ROE | -9.61% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 87.94% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.88
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.2 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.04 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)47.32%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y56.85%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)41.78%
Revenue growth 3Y60.94%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y